Berkshire Buys Dominion Energy; Stocks to Avoid: Livongo

Berkshire Buys Dominion Energy; Stocks to Avoid: Livongo

Whitney Tilson’s email to investors discussing Warren Buffett‘s Berkshire buys Dominion Energy natural gas assets in $10 billion deal; stocks to avoid: Livongo.


Q2 2020 hedge fund letters, conferences and more

Hayden Capital 2Q22 Performance Update

unnamed 12Hayden Capital's performance update for the second quarter ended June 30, 2022. Q2 2021 hedge fund letters, conferences and more Dear Partners and Friends, The markets continued to sell-off in the second quarter, especially for internet-based businesses.  This year continues to be the toughest stretch for us, since the Hayden’s inception.  Inflation concerns and the Read More

Berkshire Hathaway Buys Dominion Energy

1) It’s good to see Warren Buffett finally putting some of Berkshire Hathaway’s (BRK-B) cash hoard to work: Warren Buffett’s Berkshire buys Dominion Energy natural gas assets in $10 billion deal by CNBC. Excerpt:

  • The conglomerate is spending $4 billion to buy the natural gas transmission and storage assets of Dominion Energy.
  • Including the assumption of debt, the deal totals almost $10 billion.
  • It’s the first major purchase from Berkshire since the coronavirus pandemic and subsequent market collapse in March.
  • For Berkshire, the move greatly increases its footprint in the natural gas business.
  • With the purchase, Berkshire Hathaway Energy will carry 18% of all interstate natural gas transmission in the United States, up from 8% currently.

Stocks to Avoid: Livongo Health

2) Livongo Health (LVGO) is the latest in our “Stocks to Avoid” series (note: these are not short selling recommendations).

Livongo’s mission statement is empowering people with chronic conditions to live better and healthier lives. The company has pioneered a new category of health care it calls Applied Health Signals. Its service platform is designed to help users better cope with diabetes, hypertension, weight management, and behavioral conditions.

These are some of the most serious health conditions faced by millions of Americans. So, with its promise to provide a better solution for dealing with these diseases, Livongo won backing to become a public company in July 2019.

LVGO shares closed at $38 on their first day of trading, giving Livongo a market value above $3.7 billion.

The coronavirus pandemic has ignited increased demand for health care stocks, and Livongo shares are up nearly 300% since mid-March. But the excitement is likely more hype than reality…

Livongo’s diabetes solution is a cellular-connected interactive blood glucose meter. It comes with unlimited testing strips and allows for personalized reminders to test regularly. The company also offers live, 24/7 monitoring services for an additional charge.

Hypertension and weight management solutions are similarly designed. Livongo’s blood pressure monitor and weight scales connect to a mobile app, which monitors progress and provides advice.

It’s unclear how any of these products apply to COVID-19 patients. The virus typically produces cold- and flu-like symptoms that go away on their own. And when complications arise, they require hospitalization and significant medical intervention.

But both these scenarios play out in weeks, not months or years. COVID-19 doesn’t behave like the chronic disabilities Livongo targets.

And then there’s the matter of the company’s financials. In May, management said it expected around $300 million in revenues this year. That means that given its current $7.1 billion market cap, Livongo trades at more than 24 times forward revenues.

For 2019, Livongo reported a loss of $55 million. That figure improved to a loss of $5.6 million in the first quarter of 2020, and management celebrated its first-ever positive earnings before interest, taxes, depreciation, and amortization (“EBITDA”) period.

But getting to that adjusted $3.8 million EBITDA number required financial gymnastics that included adding back $8 billion in stock-based compensation. Even if we took it at face value and annualized these earnings to $15 million, Livongo is still valued at 475 times EBITDA.

Wall Street analysts predict the company will earn $0.60 per share in 2024. That means the stock trades for nearly 121 times earnings three and a half years out. Livongo’s business could flourish and become a significant next-generation health care provider… But for investors, making money in this stock might prove a lot more difficult.

Best regards,


Updated on

Jacob Wolinsky is the founder of, a popular value investing and hedge fund focused investment website. Jacob worked as an equity analyst first at a micro-cap focused private equity firm, followed by a stint at a smid cap focused research shop. Jacob lives with his wife and four kids in Passaic NJ. - Email: jacob(at) - Twitter username: JacobWolinsky - Full Disclosure: I do not purchase any equities anymore to avoid even the appearance of a conflict of interest and because at times I may receive grey areas of insider information. I have a few existing holdings from years ago, but I have sold off most of the equities and now only purchase mutual funds and some ETFs. I also own a few grams of Gold and Silver
Previous article Limited Time Offer – Market-Crushing Returns With Undervalued Small Caps
Next article Second $1,200 stimulus check? One more reason to believe

No posts to display